Tuesday, September 04, 2018 7:22:28 PM
I'm not really worried about the future of PPCB because of the convertible notes, or anything else because they have two patents they would like to proudly present to the world this week.
What scares me more is this: "it is time some big pharma like Pfizer or Roche or Cellgene like crocodiles take some stake in this, or show interest in this puppy!!"
When Pharma giants like these show interest in a small company like PPCB, based on my years of research, that means that the cancer cure product could really work and their intention is to destroy that product at any price
There were hundreds of Scientist, researchers or even college students who invented effective cancer medication and these same Pharma giants either did not showed any interest to invest in the company and let them die, or they buy the company and stop the project.
Yes, Chemotherapy is one of the most profitable pharmacological industry, and unfortunately, they will try to keep it that way :(
As far as this stock goes, I'm all in :) I want to ride the wave, good catalysts, strong backwinds ahead, but I would not bet on the longevity of this company once some pharma giant show interest in this puppy :)
What scares me more is this: "it is time some big pharma like Pfizer or Roche or Cellgene like crocodiles take some stake in this, or show interest in this puppy!!"
When Pharma giants like these show interest in a small company like PPCB, based on my years of research, that means that the cancer cure product could really work and their intention is to destroy that product at any price
There were hundreds of Scientist, researchers or even college students who invented effective cancer medication and these same Pharma giants either did not showed any interest to invest in the company and let them die, or they buy the company and stop the project.
Yes, Chemotherapy is one of the most profitable pharmacological industry, and unfortunately, they will try to keep it that way :(
As far as this stock goes, I'm all in :) I want to ride the wave, good catalysts, strong backwinds ahead, but I would not bet on the longevity of this company once some pharma giant show interest in this puppy :)
Recent PPCB News
- Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade • GlobeNewswire Inc. • 05/20/2026 12:45:00 PM
- Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients • GlobeNewswire Inc. • 05/19/2026 12:45:00 PM
- Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results • GlobeNewswire Inc. • 05/15/2026 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 09:30:07 PM
- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans • GlobeNewswire Inc. • 05/14/2026 02:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:18 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/10/2026 09:29:59 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/31/2026 10:12:48 AM
- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain • GlobeNewswire Inc. • 03/24/2026 12:45:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/19/2026 09:30:42 PM
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy • GlobeNewswire Inc. • 03/12/2026 12:45:00 PM
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study • GlobeNewswire Inc. • 03/10/2026 12:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/06/2026 10:22:19 PM
- Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid Tumors • IH Market News • 03/03/2026 03:34:06 PM
- Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models • GlobeNewswire Inc. • 03/03/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:19:30 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/19/2026 10:28:16 PM
- Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results • GlobeNewswire Inc. • 02/18/2026 01:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 07:54:17 PM
- Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market • GlobeNewswire Inc. • 02/05/2026 01:45:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2026 10:29:59 PM
- Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations • GlobeNewswire Inc. • 01/27/2026 01:45:00 PM
- Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia • GlobeNewswire Inc. • 01/20/2026 01:45:00 PM
- Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer • GlobeNewswire Inc. • 01/15/2026 01:45:00 PM
